Skip to content
Menu

bioAffinity Technologies, Inc. BIAF

Full chart Compare
Set alert

Price alert · BIAF

All alert types
1.85 USD -0.30 (-13.95%)

Regular-session close

1.89 +0.04 +2.16%

After hours · Nov 19, 4:10 PM ET

1.84 Day range 2.11
1.84 52-week range 80.70
YTD
-89.55%
1 year
-91.61%

5D -0.50 (-20.33%)

22.202.40FriMonTueWedThu1.94
Market cap
3.37M
Revenue (ttm)
7.32M
Profit margin
-119.41%
EPS (ttm)
-40.37
Shares out
15.58M
Forward P/E
-1.58
YTD return
-89.55%
1-year return
-91.61%
Volume
47.06K
Avg volume
3.55M
Open
2.01
Previous close
2.15
Day's range
1.84 – 2.11
52-week range
1.84 – 80.70
Beta
3.12
Price target
6.00 (+224.3%)

Key statistics

50-day average
1.28
200-day average
1.91
Enterprise value
18.47M
Price / sales
2.02
Price / book
1.84
Revenue growth
12047.40%
Free cash flow
-4.29M
Total cash
801.31K
Total debt
1.38M
Return on equity
-151.52%
Short % of float
2.85%

Fundamental scorecard

7 of 25 checks passed on BIAF’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 2 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
BIAF Revenue — quarterly 1.07M
BIAF Net income — quarterly -5.28M
BIAF EPS — quarterly -5.89

Earnings

BIAF recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-0.16——
Aug 14, 2024Jun 1, 20240.00-0.19——
May 15, 2024Mar 1, 20240.00-0.21——
Apr 1, 2024Dec 1, 20230.00-0.26——
Nov 14, 2023Sep 1, 20230.00-0.26——
Aug 14, 2023Jun 1, 20230.00-0.20——

Upgrades / downgrades

BIAF analyst upgrades and downgrades
DateFirmActionFromTo
Jul 23, 2024Maxim Groupinit—Buy

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States

News

Your note

Sign in to keep a note on BIAF — it syncs with the Stock Master app.

Insider holders

BIAF insider holders
InsiderRelationLatest transactionDateShares held
ANDERSON ROBERT ADirectorStock Award(Grant)Jun 30, 2024163,936
DIAMOND STUARTDirectorStock Award(Grant)Jun 30, 202499,088
EDWARDS JAMES MICHAELChief Financial OfficerStock Award(Grant)Nov 4, 2024113,956
GIRGENTI STEVENOfficer and DirectorStock Award(Grant)Jun 30, 20241,074,200
JOYCE ROBYDirectorStock Award(Grant)Jun 30, 2024649,745
KNIGHT PETER SDirectorStock Award(Grant)Jun 30, 2024117,455

Institution ownership

BIAF institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc1.67%260,869247.82KSep 29, 2024
Geode Capital Management, LLC0.56%87,18182.82KSep 29, 2024
Captrust Financial Advisors0.18%27,88526.49KSep 29, 2024
Sheaff Brock Investment Advisors, LLC0.13%20,00019.00KSep 29, 2024
State Street Corporation0.11%17,60016.72KSep 29, 2024
Northern Trust Corporation0.09%13,66212.98KSep 29, 2024

Fund ownership

BIAF fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.41%220,227209.22KSep 29, 2024
Fidelity Extended Market Index Fund0.30%47,31344.95KOct 30, 2024
Vanguard Extended Market Index Fund0.26%40,64238.61KSep 29, 2024
Fidelity Total Market Index Fund0.09%13,70413.02KOct 30, 2024
Fidelity Series Total Market Index Fund0.07%11,54110.96KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.06%9,4078.94KOct 30, 2024